Chimerix

Phase 3 Open-Label Brincidofovir Study

We are pleased that we reached agreement with the U.S. Food and Drug Administration (FDA) for the immediate initiation of the pilot portion of the Phase 3 Open-label Brincidofovir…  Read More

Technology Platform

Lipid-Antiviral-Conjugate Technology

Chimerix is applying its powerful Lipid-Antiviral-Conjugate Technology to existing antiviral compounds with the goal of increasing their bioavailability,…    Read More